Meeting
2020 ASCO Virtual Scientific Program
Effect of genomic and transcriptional alterations in first-line chemotherapy on subsequent immunotherapy in non-small cell lung cancer (NSCLC) patients.
Authors
Yayi He
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
Yayi He , Xiaobin Li , Shiying Dang , Guifeng Liu , Lele Song , Bo Zhu , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9614)
DOI
10.1200/JCO.2020.38.15_suppl.9614
Abstract #
9614
Poster Bd #
380
Abstract Disclosures
Similar Posters
First Author: Gaurav Singal
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah
Poster
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
First Author: Hiroki Izumi
Poster
2023 ASCO Annual Meeting
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.
First Author: Jeffrey A. Scott